Compare VIR & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIR | EMBC |
|---|---|---|
| Founded | 2016 | 1924 |
| Country | United States | United States |
| Employees | N/A | 1850 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.0M | 755.0M |
| IPO Year | 2019 | N/A |
| Metric | VIR | EMBC |
|---|---|---|
| Price | $6.23 | $12.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $28.63 | $18.50 |
| AVG Volume (30 Days) | ★ 1.9M | 562.3K |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 4.71% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.62 |
| Revenue | $16,860,000.00 | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.00 |
| Revenue Next Year | N/A | $0.27 |
| P/E Ratio | ★ N/A | $7.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $9.20 |
| 52 Week High | $11.39 | $20.63 |
| Indicator | VIR | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 52.11 | 56.06 |
| Support Level | $5.69 | $12.51 |
| Resistance Level | $6.90 | $13.03 |
| Average True Range (ATR) | 0.36 | 0.43 |
| MACD | 0.05 | 0.13 |
| Stochastic Oscillator | 50.37 | 79.39 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.